ResearcherUniversity of UtahActive in the last 2 years
Vaia Florou
Matched on ORCID iD 0000-0001-5558-753X; OpenAlex author ID A5043773782. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 33
2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 1 paper
Papers 6
- POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer Co-author DOI 10.64898/2026.03.15.711961↗
- KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. Last author DOI 10.1001/jamanetworkopen.2024.53588↗
- Gemcitabine-induced myositis in a patient with pancreatic cancer. Co-author DOI 10.1136/bcr-2024-259660↗
- Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations … Co-author DOI 10.1158/1078-0432.ccr-22-3724↗
- Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study. Co-author DOI 10.1186/s12885-022-10130-4↗
- Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. Co-author DOI 10.1200/po.20.00052↗
Closest collaborators
The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Chris Nevala-Plagemann · 5 shared papers, 2020–2025 · strength 1.11
- Paper Gemcitabine-induced myositis in a patient with pancreatic cancer. DOI 10.1136/bcr-2024-259660↗
- Paper KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. DOI 10.1001/jamanetworkopen.2024.53588↗
- Paper Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study. DOI 10.1186/s12885-022-10130-4↗
- Ignacio Garrido‐Laguna · 5 shared papers, 2020–2025 · strength 1.11
- Paper Gemcitabine-induced myositis in a patient with pancreatic cancer. DOI 10.1136/bcr-2024-259660↗
- Paper KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. DOI 10.1001/jamanetworkopen.2024.53588↗
- Paper Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study. DOI 10.1186/s12885-022-10130-4↗
- Zach Rubnitz · 2 shared papers, 2025 · strength 0.63
- Heloisa Prado Soares · 2 shared papers, 2023–2025 · strength 0.43
- Paper KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. DOI 10.1001/jamanetworkopen.2024.53588↗
- Paper Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unv… DOI 10.1158/1078-0432.ccr-22-3724↗
- Carter Norton · 1 shared paper, 2025 · strength 0.27
- Benjamin D. Greenbaum · 1 shared paper, 2026 · strength 0.19
- Olca Baştürk · 1 shared paper, 2026 · strength 0.19
- Marinela Capanu · 1 shared paper, 2026 · strength 0.19
- Dana Pe'er · 1 shared paper, 2026 · strength 0.19
- Vinod P. Balachandran · 1 shared paper, 2026 · strength 0.19
- Anna M. Varghese · 1 shared paper, 2026 · strength 0.19
- Fergus Keane · 1 shared paper, 2026 · strength 0.19
- Kevin C. Soares · 1 shared paper, 2026 · strength 0.19
- Benoı̂t Rousseau · 1 shared paper, 2026 · strength 0.19
- Caitlin A. McIntyre · 1 shared paper, 2026 · strength 0.19
- Akimasa Hayashi · 1 shared paper, 2026 · strength 0.19
- Wungki Park · 1 shared paper, 2026 · strength 0.19
- Eileen Mary O'Reilly · 1 shared paper, 2026 · strength 0.19
- Haochen Zhang · 1 shared paper, 2026 · strength 0.19
- Danny N. Khalil · 1 shared paper, 2026 · strength 0.19
- Marc Hilmi · 1 shared paper, 2026 · strength 0.19
- Nuray Tezcan · 1 shared paper, 2026 · strength 0.19
- Fiyinfolu O. Balogun · 1 shared paper, 2026 · strength 0.19
- Christine A. Iacobuzio–Donahue · 1 shared paper, 2026 · strength 0.19
- Michael Jon Pishvaian · 1 shared paper, 2026 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.